Search / Trial NCT00000561

Mode Selection Trial in Sinus Node Dysfunction (MOST)

Launched by MT. SINAI MEDICAL CENTER, MIAMI · Oct 27, 1999

Trial Information

Current as of December 27, 2024

Completed

Keywords

ClinConnect Summary

BACKGROUND:

Permanent pacing is estimated to cost one billion dollars annually in health care costs in the United States. Initially, pacing was primarily confined to ventricular pacing with limited sensing, programming and pacing capacity. Tremendous growth has occurred in pacing technology, making available dual chamber pacing with sophisticated sensing, pacing, and rate control. These more advanced pacemakers are more costly and complicated to place surgically.

One of the most common indications for pacing is sick sinus syndrome. Initial therapy is usually medical to inhibit the tachyar...

Gender

ALL

Eligibility criteria

  • Men and women with sick sinus syndrome.

Trial Officials

Gervasio Lamas

Icahn School of Medicine at Mount Sinai

Kerry Lee

Duke University

About Mt. Sinai Medical Center, Miami

Mount Sinai Medical Center in Miami is a leading healthcare institution renowned for its commitment to advanced medical research and clinical excellence. As a prominent sponsor of clinical trials, the center focuses on innovative therapies and cutting-edge treatments across various medical disciplines. With a team of experienced researchers and healthcare professionals, Mount Sinai aims to enhance patient care through rigorous scientific inquiry and collaboration, ultimately contributing to the advancement of medical knowledge and the improvement of health outcomes in the community and beyond.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials